Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (230)	3/8/1999 6:14:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1475

Protein Design Labs Announces Positive Results in Phase II Trial of Zenapax For the Treatment of Acute Graft Versus Host Disease FREMONT, Calif., March 8 /PRNewswire/ -- Protein Design Labs, Inc. (PDL, the "Company") (Nasdaq: PDLI) today announced that Zenapax(R) (daclizumab) has demonstrated efficacy in patients with acute graft versus host disease (GVHD) in a Phase II trial. The results were presented at the 1999 Tandem Bone Marrow Transplant Meeting in Keystone, Colorado on March 6, 1999, by investigator Nancy A. Kernan, M.D., Associate Attending Physician on the Bone Marrow Transplantation Service at Memorial Sloan-Kettering Cancer Center. The trial examined two dosing schedules of Zenapax in forty-three allogeneic bone marrow transplant recipients with advanced or steroid refractory GVHD. The first twenty-four patients were treated with Zenapax at 1 mg/kg on days 1, 8, 15, 22 and 29. The complete response rate was 29% on day 43, and 29% of the patients survived to day 120. An additional 19 patients were treated with Zenapax at 1 mg/kg on days 1, 4, 8, 15 and 22. In these patients, the complete response rate on day 43 was 47%, and survival on day 120 was 53%. The complete response rates by organ involved with GVHD were 73% for skin, 70% for the gut and 17% for liver. There were no serious side effects attributed to Zenapax. (snip)